











































Prevalence and duration of non-motor symptoms in prodromal
Parkinson's Disease
Citation for published version:
The ICICLEPD study group & Duncan, GW 2019, 'Prevalence and duration of non-motor symptoms in
prodromal Parkinson's Disease', European Journal of Neurology. https://doi.org/10.1111/ene.13919
Digital Object Identifier (DOI):
10.1111/ene.13919
Link:




European Journal of Neurology
Publisher Rights Statement:
This is the author's peer-reviewed manuscript as accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.










This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/ene.13919 
This article is protected by copyright. All rights reserved. 
DR. RORY  DURCAN (Orcid ID : 0000-0002-8897-8737) 
DR. RACHAEL ASHLEIGH LAWSON (Orcid ID : 0000-0003-2608-8285) 
DR. GORDON WILLIAM DUNCAN (Orcid ID : 0000-0001-7654-3771) 
 
Article type      : Original Article 
 
Prevalence and duration of non-motor symptoms in prodromal Parkinson’s Disease 
 
Rory Durcan, MRCPI, MSc, 
1
 Louise Wiblin, MRCP, 
1
 Rachael A Lawson, PhD,
1
 Tien K. 
Khoo, MRCP, PhD, 
2,3
  Alison J. Yarnall MRCP, PhD
1
, Gordon W. Duncan MRCP, PhD
4
 
David J. Brooks, MD, DSc 
1,5
, Nicola Pavese FRCP, MD, PhD
1,5
,  David J. Burn FRCP, MD 
6
,  on behalf of the ICICLE-PD study group 
1. Institute of Neuroscience, Newcastle University, Newcastle Upon Tyne, UK 
2. School of Medicine & Menzies Health Institute Queensland, Griffith University, 
Queensland, Australia 
3. School of Medicine, University of Wollongong, Wollongong, New South Wales, 
Australia 
4. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK 
5. Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, 
Nørrebrogade 44, 8000, Aarhus, Denmark 












This article is protected by copyright. All rights reserved. 
Corresponding author: 
Rory Durcan,  
Institute of Neuroscience 
Campus for Ageing & Vitality  
Newcastle Upon Tyne, NE4 5PL. UK 




Running Title: Prevalence of prodromal NMS in PD 
 
Key words: Parkinson’s, Prodromal, Non-motor symptoms, Gender, Motor  
 
Disclosure of conflict of interest 
R. Durcan has nothing to disclose. 
L. Wiblin has no financial interests, patents or any other disclosures connected to this work. 
R. A. Lawson has nothing to disclose. 
T.K Khoo has nothing to disclose. 
A.J Yarnall reports other from Teva-Lundbeck, grants from Newcastle NIHR BRC, other 
from UCB,  outside the submitted work; . 
G.W DUNCAN has nothing to disclose. 
D.J. Brooks reports grants and personal fees from General Electric Healthcare, personal fees 
from Biogen, outside the submitted work;  
N. Pavese has nothing to disclose. 










This article is protected by copyright. All rights reserved. 
Study Funding 
This study was funded by Parkinson’s UK (J-0802). The research was supported by the 
Lockhart Parkinson’s Disease Research Fund, the UK NIHR Biomedical Research Centre for 
Ageing and Age-related Disease award to the Newcastle upon Tyne Hospitals NHS 
Foundation Trust and the NIHR Biomedical Research Centre funding University of 
Cambridge and Addenbrooke’s Hospital.  
 
Abstract 
Background: The prevalence and duration of NMS in prodromal PD has not been 
extensively studied. The aim of this study was to determine the prevalence and duration of 
prodromal NMS (pNMS) in a cohort of recently diagnosed PD patients.  
Methods: We evaluated the prevalence and duration of prodromal NMS in early PD patients 
(n= 154). NMS were screened for using the Nonmotor Symptom Questionnaire (NMS 
Quest). We subtracted the duration of the presence of each individual NMS reported from the 
duration of earliest motor symptom. NMS whose duration preceded the duration of motor 
symptoms were considered a pNMS. Individual pNMS were then grouped into relevant 
pNMS clusters based on the NMSQuest domains. 
Motor subtypes were defined as tremor dominant (TD), postural instability/gait difficulty 
(PIGD) and indeterminate type according to the MDS-UPDRS revision.  
Results: pNMS were experienced by 90.3% of PD patients and the median number 
experienced were 4 (IQR: 2 -7). A gender difference in pNMS experienced existed, with 
males reporting more sexual dysfunction, forgetfulness, dream re-enactment. Conversely, 
females reported more unexplained weight change and anxiety. 
There was a significant association between any prodromal gastrointestinal symptoms 
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p=0.016) with the PIGD phenotype. Further analysis revealed that total pNMS was not 
significantly associated with having PIGD phenotype (OR= 1.105, 95% CI=0.99-1.21, 
p=0.068).  
Conclusion: pNMS are common and a gender difference in pNMS experienced in prodromal 
PD may exist. PIGD phenotype had a higher prevalence of prodromal gastrointestinal and 
urinary tract symptoms. 
 
Introduction 
Clinically, PD has been defined by the presence of motor deficits such as bradykinesia, 
tremor, rigidity and postural instability 
1
. However, PD patients also experience a variety of 
other non-motor symptoms (NMS) such as mood disorders, autonomic disturbances, 
cognitive impairment and sleep dysfunction throughout their disease trajectory.   
 
NMS can precede motor symptoms indicating a prodromal symptomatic stage exists in PD. 
The presence of hyposmia, constipation, depression and idiopathic REM (rapid eye 
movement) Sleep Behaviour Disorder (RBD) are well-established symptoms that 




The emerging concept of a prodromal phase of PD has led the International Parkinson and 
Movement Disorder Society (IPMDS) task force to propose a new definition of PD; this 
definition would not base the diagnosis solely on motor symptoms but would also incorporate 
NMS 
3
. However, there is a paucity of research investigating the frequency and time of onset 
of NMS before the onset of the motor phase of PD.  Furthermore, little is known about the 
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subsequent PD motor phenotypes: tremor dominant (TD), postural instability gait difficulty 




We aimed to explore the frequency and time of onset of NMS before motor symptoms 
(prodromal NMS, pNMS) and the role of gender on pNMS experienced. We hypothesised 




Patient eligibility criteria and recruitment 
 
Recently diagnosed PD patients from Newcastle-upon-Tyne and Gateshead were invited to 
take part in the study between June 2009, and December 2011 as part of the Incidence of 
Cognitive Impairment in Cohorts with Longitudinal Evaluation-Parkinson’s disease 
(ICICLE-PD) study 
5
.   
 
All participants were diagnosed by a movement disorders specialist according to the UK 
Brain Bank criteria 
1
. Exclusion criteria comprised the following: drug-induced parkinsonism 
secondary to exposure to dopamine receptor blocking agent at the onset of symptoms; 
vascular parkinsonism; and atypical forms of parkinsonism such as progressive supranuclear 
palsy, multiple system atrophy, or corticobasal degeneration, according to accepted 
diagnostic criteria 
6
. Participants were also excluded if they had insufficient working 
knowledge of English, defined as being unable to perform the assessments and questionnaires 
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defined a Mini-Mental State Examination (MMSE) score <24, fulfilling DSM-IV criteria for 
dementia 
7 




The study was approved by the Newcastle and North Tyneside Research Ethics Committee 
and performed according to the Declaration of Helsinki. All participants provided informed 
written consent.  
 
Assessments 
PD participants were rated for disease severity by Hoehn & Yahr staging and motor severity 
using the MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III. Motor 
subtypes were defined as TD, PIGD and indeterminate type according to the methods 
described by Jankovic et al 
9
. Due to the small numbers of indeterminate motor phenotype in 
the cohort, only comparisons between motor subtype of TD and PIGD were conducted. 
Levodopa equivalent daily dose (LEDD) was calculated for all dopaminergic medications 




Global cognition was assessed using the MMSE
 
and the Montreal Cognitive Assessment 
(MoCA). Depressive symptoms were also assessed using the Geriatric Depression Scale 
(GDS-15).  
 
Assessment of NMS and prodromal NMS. 
Participant NMS burden was assessed at initial patient screening visit using the Non-Motor 
Symptom Questionnaire (NMS-Quest) 
11 
. The NMS-Quest is 30-item questionnaire, which 
comprises ten domains of NMS: gastrointestinal symptoms, urinary tract symptoms, sexual 
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of other complaints such as weight loss.   A positive response about the presence of a NMS 
on the screening questionnaire, elicited a further question about the estimated duration of the 
NMS symptom. 
 
In order to determine the presence or absence of pNMS, we subtracted the duration of the 
presence of each individual NMS reported from the duration of earliest motor symptom. 
NMS whose duration preceded the duration of motor symptoms were considered a pNMS; 
NMS which occurred after motor symptom onset were not classified as pNMS. The presence 
and duration of each NMS in excess of the duration of motor symptoms was recorded as a 
pNMS in months.  
 
Individual pNMS symptoms were further classified into seven distinct non-motor subtypes 
based on the symptom domains covered in the NMS-Quest. These were gastrointestinal 
symptoms, urinary tract symptoms, sexual dysfunction, cardiovascular symptoms, 
neuropsychiatric and cognitive symptoms, sleep dysfunction symptoms and miscellaneous 
symptoms. In order to be included in a prodromal non-motor subtype, a participant had to 
have at least one prodromal NMS consistent with that NMS domain. 
 
Statistical analysis 
Statistical analyses were performed using SPSS software (Version 22, Armonk, NY: IBM 
Corp). Data were assessed for a normality using Kolmogorov-Smirnov tests. The mean and 
standard deviation were computed for parametric variables, the median and interquartile 
range for non-parametric variables. Continuous and count data were compared using the 
parametric tests (T- test) or non-parametric test (Mann Whitney U) as appropriate, and 
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Hierarchical logistic regression was used to determine significant predictors of PIGD motor 
phenotype. Backwards stepwise logistic regression was used to produce a basic model of 
predictors involving age, gender and LEDD. Non-significant predictors were excluded. 
Significant predictors were then included to give a basic model; total pNMS and pNMS 
domains (present or absent) were then individually added to the model. A p-value of <0.05 
was deemed to be significant for all analysis. 
 
Results 
154 participants with a diagnosis of idiopathic PD were identified from the ICICLE-PD 
cohort (Table 1). Participants had a mean age of 66.4±10.4 years and had a median PD 
duration of 4.7 months; 64.9% (n=100) were male. 
 
The presence or absence of pNMS was calculated; 139 (90.3%) of participants experienced 
pNMS (Table 2). The median number of pNMS experienced by the PD patients was 4 (IQR: 
2 -7). The most common individual pNMS experienced were: hyposmia (39.6%); 
forgetfulness/memory complaints (36%); sialorrhea (33.8%); urinary urgency (30.2%); and 
anxiety (30.2%) (Table 2). Gender differences in pNMS experienced were observed, with 
males reported significantly more sexual dysfunction (22% vs 3.7%, respectively, p=0.003), 
forgetfulness (38% vs 22.2%, respectively, p=0.046), dream re-enactment (29% vs 14.8%, 
respectively, p=0.049) compared to female participants (Table 2). Conversely, females 
reported significantly greater unexplained weight change (13% vs 4%, respectively, p=0.039) 
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Individual pNMS symptoms were classified into prodromal NMS domains. The most 
frequent pNMS domains were gastrointestinal tract (67.5%), sleep (52.6%), urinary tract 
(42.2%), cardiovascular system (32.5%) and miscellaneous systems (22.1%) (Table 3). In 
terms of the median duration of pNMS preceding motor symptom onset, sleep dysfunction (-
66 months), sexual dysfunction (-60 months) and gastrointestinal tract symptoms (-
59months) had the longest latency period (Table 3).When pNMS were grouped into symptom 
clusters, males experienced significantly more symptoms related to sexual problems 
compared to female participants (26% vs 5.6%, respectively, p=0.002, Table 3); females 
experienced significantly more miscellaneous symptoms compared to male participants 
(40.7% vs 19%, respectively, p=0.004). 
 
Prodromal NMS differences between motor phenotypes were then evaluated (Table 4). 
Participants classified as PIGD were significantly older than TD subtypes (68.4±9.2 vs. 
63.6±11), respectively, p=<0.01; Table 4). The Geriatric Depression Scale (GDS-15) scores 
were slightly higher for the PIGD subtype compared to the TD subtype (3.12±2.4 vs. 2.27 ± 
2.3, respectively, p=0.01), but were still below the cut-off (≥5) for possible depression in all 
subtypes. Participants with PIGD subtype were prescribed significantly higher doses of 
LEDD compared with TD subtype (203.0 ± 138.6 vs 151.4 ±165.4, respectively, p<0.01) 
(Table 4). 
 
Predictors of PIGD motor phenotype were then determined, first using logistic univariate 
regression. Significant predictors included age, LEDD, GDS-15, number of pNMS, 
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Backwards regression revealed that only age (β=0.061, OR=1.06, CI=1.02-1.11, p=0.003) 
was a significant predictor of PIGD phenotype; a basic model was then constructed with age 
and LEDD. LEDD was included in the basic model as it was an important confounding 
variable although it was not a significant predictor of PIGD phenotype.  Total pNMS and 
pNMS domains were then individually added to the model. Analysis revealed that total 
pNMS was not a significant predictor of having PIGD phenotype (OR= 1.10, CI=0.99-1.21 
p>0.05). However, there was a significant association between any prodromal gastrointestinal 
symptoms (OR=2.30, 95% CI=1.08-4.89, p<0.05) and urinary symptoms (OR=2.54, 95% 
CI=1.19-5.35, p<0.05) with the PIGD phenotype. PD patients with prodromal gastrointestinal 
symptoms were thus 2.3 times more likely to develop PIGD phenotype, after controlling for 
age and LEDD.  Similarly, PD participants with prodromal urinary symptoms were 2.5 times 
more likely to evolve into a PIGD rather than TD phenotype, after controlling for age and 




Our study strengths the notion of NMS antedating motor symptoms in PD by assessing the 
presence and time of onset of the full spectrum of pNMS using a validated NMS 
questionnaire (NMS-Quest) in a recently diagnosed PD population. Interpretation of previous 
studies evaluating the frequency and duration of onset of pNMS is limited by study 
methodological variability; the lack of direct patient evaluation 
2
, a long duration from PD 
diagnosis to study enrolment 
12
, utilisation of non-validated, custom-made NMS 
questionnaires 
13
 or studying only limited subsets of the spectrum on pNMS in PD cohorts 
14
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Our study found 90% of participants reporting at least one pNMS while the median number 
of pNMS experienced was four.  Prior studies have reported higher prevalence of prodromal 
symptoms than our study likely due to methodological differences.  A retrospective study 
conducted via telephone interview with PD patients and controls, using a custom made 
questionnaire reported a 98.9% of PD subjects having one or more prodromal symptom but 
this study incorporated prodromal motor symptoms as well as pNMS 
2
. Similarly, another 
retrospective study, with a long mean duration from PD diagnosis of 7.6 ± 5.6 years, reported 
98.9% of subjects experienced prodromal symptoms preceding a diagnosis of PD 
12
.   
 
Based on the Braak model of the hypothesised spread of alpha-synuclein in PD, alpha 
synuclein accumulation begins in the gut before progressing via the vagus nerve to the brain 
17
. Therefore, gastrointestinal (GI) features should be a prominent early manifestation PD. 
Our study encompassed questions focusing on the GI tract which had not been previously 
reported, such as the prevalence of prodromal weight loss (7.1%), dysphagia (11.7%) and 
incomplete bowel emptying (16.9%). Prevalence of prodromal constipation symptoms 
(24.7%) and hyposmia (35.7%) have previously be reported and are approximately in line 
with published work 
2,13
.  Clustering prodromal GI symptoms together revealed 67.5% of PD 
subjects had one or more GI symptoms antedating motor symptom development in PD which 
is consistent with the Braak model of early GI involvement in PD. Moreover, GI clusters, as 
well as urinary tract clusters, of pNMS were significantly associated with PIGD motor 
phenotype. To the best of our knowledge, no other study has shown an association between 
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In contrast to other studies, the prevalence of prodromal memory complaints (32.8%) and 
unexplained pain (20.8%) in our study is substantially higher compared with prior reported 
work 
12,13
. Meanwhile, the prevalence of apathy (14.8%) and hyperhidrosis (2.6%) is 
significant lower than in other studies.  The variability in reported prevalence rate of pNMS 
may be due to individual’s perception and reporting of NMS. Many NMS progress slowly 
and are of mild severity, so underappreciated in the early stages 
12
. Furthermore, cognitive 
impairment has also been associated with underestimation of NMS and loss of awareness of 
hyposmia has been reported to occur in PD-MCI 
18
. It is possible cognitive performance may 
have impacted on symptom recall in our study as mean MOCA  score was 25.2 (± 3.7) and 
previously published work from the ICICLE-PD study showed that among the 5 cognitive 
domains, memory impairment was the most common domain affected in PD participants at 
1.5 SDs below normative values (15.1%) 
5
. However, all participants enrolled in the study 
underwent rigorous assessment to exclude dementia.  
 
Gender has been reported as an independent predictor of NMS reported in early PD studies.  
Females have been reported to experience more anxiety, pain, depression and sleep 
disturbance 
19-21 
while males have been reported to experience more apathy and sexual 
dysfunction 
22-24
. However, there is a paucity of work examining the influence of gender on 
NMS in the prodromal period.  We found gender difference in terms of specific pNMS 
experienced, namely sexual dysfunction, forgetfulness and dream re-enactment being more 
prevalent in males, and unexplained weight change and anxiety in females. Gender 
differences in perceived pNMS prevalence may be reflective of what each gender interprets 
to be important rather than any underlying early pathological evolutionary difference between 
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There are some limitations in our study. The retrospective design of this study may have 
introduced recall error and thereby affected the accuracy of the data. Attempts were made to 
minimise recall errors by having experienced movement disorder physicians conduct face-
face interviews with recently diagnosed PD patients including a caregiver interview. Another 
limitation is the lack of a validated prodromal questionnaire to evaluate pNMS. The NMS-
Quest was adapted to identify prodromal NMS as is has been extensively used to investigate 
NMS in de novo, early PD. However, its sensitivity and specificity for evaluating prodromal 
symptoms in ‘at risk’ PD cohorts have not been established. Therefore, it is entirely possible 
some of the symptoms reported in this study are not related to an evolving Lewy body 
disorder but other underlying medical conditions or non-specific normal age related 
symptoms.  
 
In conclusion, our study has shown pNMS are prevalent, antedate motor symptoms in some 
cases by several years and distinct gender differences exist in the pNMS experienced. 




The ICICLE-PD study group thanks all participants and their carers for their contributions 
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Table 1 Characteristics of patients with Parkinson's Disease 
Variable PD (n=154) 
Gender - Male/Female n(%) 100 (64.9)/ 54 (35.1) 
Age (years) 66.4 (10.4) 
Duration of PD (months) median(IQR) 4.7 (2.6 – 8.1) 
MDS-UPDRSIII 26.9 ± 12.1 
H&Y staging 2.0 ± 0.7 
H&Y Stage n(%)  
- I 35 (22.7) 
- II 88 (57.1) 
- III 30 (19.5) 
- IV 1 (0.6) 
- V 0 
PD medication treatment n(%)  
- Drug naïve 19 (12.3) 
- Levodopa 45 (29.2) 
- Dopaminergic agonists 57 (37) 
- MAOB inhibitor 73 (47.4) 
-  LEDD (mg/day) 178.1 ± 148.2 
Motor phenotype n(%)  
- PIGD 78 (50.6) 
- Indeterminate 13 (8.4) 
- TD 63 (40.9) 
MMSE 28.6 ± 1.3 
MoCA
a 
25.2 ± 3.7 
GDS-15 2.8 ± 2.6 
 
Figures are mean ± SD unless otherwise stated. 
IQR= interquartile range; PIGD = Postural instability gait difficulty motor subtype; 
TD = Tremor dominant motor subtype; PD= Parkinson’s disease; MMSE=Mini 
Mental state examination; MoCA= Montreal Cognitive Assessment; MDS-UPDRS = 
Movement Disorder Society – revised Unified Parkinson’s Disease Rating scale; 
LEDD = Levodopa equivalent daily dose; GDS-15 = Geriatric Depression Scale-15; 
MAOB= Monoamine oxidase B; H&Y= Hoehn & Yahr. 
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Table 2. Prevalence NMS at screening and prodromal non-motor symptoms in PD patients 













pNMS in males vs. females 









No. of PD patients 
with symptoms  
139 
(90.3) 
     
No pNMS experienced 
median no. (IQR)  
4 (2-7)  4 (2-6.25) 4 (2-7) U=2850.5 0.649 
Gastrointestinal Tract       
Sialorrhea 47 
(30.5) 
-33 (-18 to-3) 34 (34) 13 (24.1) χ2 =1.6      0.202 
Dysphagia 18 
(11.7) 
-25 (-27 to-4) 11 (11) 7 (13) χ2 =0.1 0.718 
Nausea 3 (1.9) -25 (-48 to-
24) 





24 (24) 14 (25.9) χ2 =0.1 0.791 
Bowel incontinence 4 (2.6) -175 (-516 
to-1) 










32 (32.0) 23 (42.6) χ2 =1.7 0.191 
Weight change 
(unexplained) 
11 (7.1) -13 (-12 to-1) 4 (4.0) 7 (13.0) χ2 =4.2 0.039 
Urinary tract       









18 (18) 11 (20.4) χ2 =0.1 0.72 
Sexual Function       




22 (22.0) 2 (3.7) χ2 =8.9 0.003 
Impaired Libido 15 (9.7) -56 (-96 to-
18) 
12 (12) 3 (5.6) χ2 =1.7 0.198 
Cardiovascular       
Orthostatic symptoms 28 
(18.2) 
-23 (-31 to-2) 20 (20.0) 8 (14.8) χ2 =0.6 0.426 
Falls 16 
(10.4) 
-13 (-12 to-2) 11 (11.0) 5 (9.3) χ2 =0.1 0.735 
Lower Limb swelling 17 
(11.0) 
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Neuropsychiatric and 
cognitive 
      
Forgetfulness/memory 50 
(32.5) 
-36 (-36 to-8) 38 (38) 12 (22.2) χ2 =4.0 0.046 
Impaired concentration 25 
(16.2) 





22 (22.0) 20 (37.0) χ2 =4.0 0.046 
Low mood 27 
(17.5) 
-20 (-31 to-7) 15 (15) 12 (22.2) χ2 =<0.1 0.261 
Loss of interest/ apathy 22 
(14.3) 
-20 (-25 to-8) 13 (13) 9 (16.7) χ2 =0.4 0.535 
Delusions 0 (0) NA 0 (0) NA 0 (0) NA NA 
Visual Hallucinations 12 (7.8) -12 (-17 to-4) 7 (7.0) 5 (9.3) χ2 =0.2 0.618 
Sleep       




25 (25) 7 (13) χ2 =3.1 0.079 
Insomnia 10 (6.5) -28 (-51 to-
11) 
5 (5) 5 (9.3) χ2 =1.0 0.306 




29 (29.0) 8 (14.8) χ2 =3.9 0.049 




25 (25.0) 10 (18.5) χ2 =0.8 0.36 
Restless legs 28 
(18.2) 
-70 (-49 to-6) 14 (14.0) 14 (25.9) χ2 =3.4 0.067 
Miscellaneous       
Diplopia 11 (7.1) -112 (-109 
to-19) 
6 (6.0) 5 (9.3) χ2 =0.6 0.454 
Hyperhydrosis 4 (2.6) -48 (-93 to-
11) 
1 (1.0) 3 (5.6) χ2 =2.9 0.090 
Pain (unexplained) 32 
(20.8) 
-15 (-23 to-6) 17 (17) 15 (27.8) χ2 =2.4 0.116 
NMS= Non-motor symptoms, pNMS=prodromal non-motor symptoms, PD = Parkinson’s 
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Table 3: Prevalence and median duration of Prodromal NMS according to distinct prodromal 
NMS domains 
Symptom Group PD pNMS 
 





median months  
(IQR) 
 
pNMS in males vs. females 




(n=54)   
n (%) 
χ2 p-Value  
Gastrointestinal 
Tract 




37 (68.5) <0.1 0.848 
Urinary tract 65 (42.2) -45 (-126 to -14) 38 
(38.0) 
20 (37.0) <0.1 0.906 
Sexual function 32 (20.8) -60 (-119 to -29) 26 
(26.0) 
3 (5.6) 9.6 0.002 
Cardiovascular 50 (32.5) -12 (-48 to -5) 35 
(35.0) 
15 (27.8) 0.8 0.361 
Neuropsychiatric 
and cognitive 
19 (12.3)  -39 (-132 to-14) 55 (55) 30 (55.6) <0.1 0.947 
Sleep 81 (52.6) -66 (-237 to-19) 55 
(55.0) 
25 (46.3) 1.1 0.302 
Miscellaneous 34 (22.1) -12 (-48 to-8) 19 
(19.0) 
22 (40.7) 8.5 0.004 
NMS= Non-motor symptoms, pNMS= prodromal non-motor symptoms, PD = Parkinson’s 
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Test statistic P Value 
Gender Male /Female n(%) 56(71.8)/ 22(28.2) 36(57.1)/27(42.9) χ2= 3.3 0.069 
Age  68.4 (9.2)1 63.6 (10.97)3 t=2.7 0.007 
Duration of PD (months) 6.2 (4.8) 5.7 (4.4) U=2376.0 0.737 
LEDD (mg/day) 203.04 ± 138.61 151.4 ± 165.4 U=1684.5 0.001 
MMSE 28.53 (1.3) 28.8 (1.3) U=2081.0 0.106 
MoCAa 24.77 (3.6) 25.6 (3.7) U=1709.0 0.117 
GDS-15 3.12 (2.4)3 2.3 (2.3)1 U=1849.5 0.011 
MDS-UPDRS III  26.96 (12.1) 26.2 (12.1) U=2315.0 0.556 
Figures are mean(SD) unless otherwise stated. Significant results are highlighted in bold. 
Abbreviations: PIGD = Postural instability gait difficulty motor subtype; TD = Tremor 
dominant motor subtype; PD= Parkinson’s disease; MMSE= Mini-Mental state examination; 
MoCA= Montreal Cognitive Assessment; MDS-UPDRS = Movement Disorder Society – 
revised Unified Parkinsons’ Disease Rating scale; LEDD = Levodopa equivalent daily 
dosag; GDS-15 = Geriatric Depression Scale-15. 
 
a MoCA completed in 140 patients with PD  
 
 
 
 
 
 
 
 
 
 
 
